

UCLA

UCLA Previously Published Works

Title

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Permalink

<https://escholarship.org/uc/item/2w09g0d8>

Journal

BMC genomics, 19(1)

ISSN

1471-2164

Authors

Pine, P Scott
Lund, Steven P
Parsons, Jerod R
et al.

Publication Date

2018-03-01

DOI

10.1186/s12864-018-4496-1

Peer reviewed

METHODOLOGY ARTICLE

Open Access



Summarizing performance for genome scale measurement of miRNA: reference samples and metrics

P. Scott Pine^{1*}, Steven P. Lund², Jerod R. Parsons¹, Lindsay K. Vang¹, Ashish A. Mahabal³, Luca Cinquini⁴, Sean C. Kelly⁴, Heather Kincaid⁴, Daniel J. Crichton⁴, Avrum Spira⁵, Gang Liu⁵, Adam C. Gower⁵, Harvey I. Pass⁶, Chandra Goparaju⁶, Steven M. Dubinett^{7,8}, Kostyantyn Krysan⁷, Sanford A. Stass⁹, Debra Kukuruga⁹, Kendall Van Keuren-Jensen¹⁰, Amanda Courtright-Lim¹⁰, Karol L. Thompson¹¹, Barry A. Rosenzweig¹¹, Lynn Sorbara¹², Sudhir Srivastava¹² and Marc L. Salit¹

Abstract

Background: The potential utility of microRNA as biomarkers for early detection of cancer and other diseases is being investigated with genome-scale profiling of differentially expressed microRNA. Processes for measurement assurance are critical components of genome-scale measurements. Here, we evaluated the utility of a set of total RNA samples, designed with between-sample differences in the relative abundance of miRNAs, as process controls.

Results: Three pure total human RNA samples (brain, liver, and placenta) and two different mixtures of these components were evaluated as measurement assurance control samples on multiple measurement systems at multiple sites and over multiple rounds. In silico modeling of mixtures provided benchmark values for comparison with physical mixtures. Biomarker development laboratories using next-generation sequencing (NGS) or genome-scale hybridization assays participated in the study and returned data from the samples using their routine workflows. Multiplexed and single assay reverse-transcription PCR (RT-PCR) was used to confirm in silico predicted sample differences. Data visualizations and summary metrics for genome-scale miRNA profiling assessment were developed using this dataset, and a range of performance was observed. These metrics have been incorporated into an online data analysis pipeline and provide a convenient *dashboard* view of results from experiments following the described design. The website also serves as a repository for the accumulation of performance values providing new participants in the project an opportunity to learn what may be achievable with similar measurement processes.

Conclusions: The set of reference samples used in this study provides benchmark values suitable for assessing genome-scale miRNA profiling processes. Incorporation of these metrics into an online resource allows laboratories to periodically evaluate their performance and assess any changes introduced into their measurement process.

Keywords: microRNA, miRNA, Reference samples, Process controls, Dashboard

* Correspondence: p.scott.pine@nist.gov

¹Joint Initiative for Metrology in Biology, National Institute of Standards and Technology, 443 Via Ortega, Stanford, CA 94305, USA

Full list of author information is available at the end of the article




© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Studies to identify potential biomarkers typically involve comparing two conditions and identifying features that distinguish the two classes; for example, disease versus normal or treated versus control. Quality measurements made during this discovery phase are essential for the success of all subsequent phases of biomarker development. Reference samples, with known differences, can enable laboratories to assess and improve their ability to detect relevant biomarkers. Within the framework of the Early Detection Research Network (EDRN) of the National Cancer Institute [1], we are developing a measurement assurance paradigm for genome-scale measurement systems currently used for microRNA (miRNA) biomarker discovery.

Comparisons of the results for genome-scale measurements of two different biological samples or two different reference samples have been used to assess both microarray [2, 3] and RNA sequencing (RNAseq) measurements of messenger RNA (mRNA) [4]. Evaluations derived from this type of comparison are limited to metrics such as concordance of gene lists and correlations of rank order because, in both cases, the true difference between samples is not known. For both microarray and RNAseq, titration designs have also been used, which provide some information regarding signal trends [4, 5].

Composite reference samples with designed-in differences provide additional metrics for performance assessment and have been demonstrated to be useful with both microarrays [6–9] and RNAseq [10]. These same technologies have been applied more recently to profiling miRNA, a class of small non-protein-coding RNAs that regulate the expression of hundreds of target genes by translational repression, controlling biological functions involved in differentiation and development. Characterizing miRNA measurements on multiple platforms has been performed with biological samples [11] and titrations of biological samples [12]. In an interlaboratory study spanning multiple rounds of measurement, we demonstrate the utility of one of these mixture designs [9], a three component reciprocal ratio design (Fig. 1) for assessing *miRNA* measurement performance. Metrics for summarizing genome-scale measurement of *mRNA*: diagnostic accuracy [7, 8], reliable region of the dynamic range [9], and sample composition [10] were evaluated; and a revised metric for estimating the reliable region based on deviations from predicted values is introduced. Multiple data visualizations and metrics have been combined into a single standardized view, or “dashboard”, for each participant and round (see Fig. 2 for an example). These are available in Additional file 1. Representative panels are described in detail in the results.



Results


Selection of human tissue total RNA

Previous studies have demonstrated the feasibility of using a pair of reference mixtures with designed-in differences to provide performance benchmarks [6–10]. These rely on a combination of pure total RNA components with a large number of transcripts that are distributed across a broad dynamic range of relative abundance. Each component should contain a subset of miRNA that are either unique to that tissue or enriched relative to the other two components. These tissue-selective miRNAs will be used in metrics to assess assay performance. The tissue-selectivity can be quantified [7] and used to assess whether a sufficient number of differentially abundant miRNA are available in each subset to span the dynamic range of the measurement process. Laboratories performing biomarker discovery may prefer one of the components be similar in nature to the tissue being profiled in their own research.

To select components for reference mixtures described in this paper, a published study comparing the miRNA expression profiles of nine different tissues using both microarrays and RT-PCR was utilized [13]. The two sources of human RNA with the most tissue-selective content were placenta followed by brain. These two tissue RNAs were used as variable components in a reciprocal two-to-one design, with liver as the invariable (one-to-one) component (Fig. 1) [14].

In silico modeling

The miRNA signals in each mixture should be an additive and linear combination of the signals from pure tissue components [6–10]. Therefore, an expected signal and predicted ratio can be calculated based upon the



fractional proportion of each tissue component in a mixture using the following equations:

$$S_{i,Mix1} = (S_{i,L} \cdot \Phi_{L,1}) + (S_{i,B} \cdot \Phi_{B,1}) + (S_{i,P} \cdot \Phi_{P,1}) \quad (1)$$

$$S_{i,Mix2} = (S_{i,L} \cdot \Phi_{L,2}) + (S_{i,B} \cdot \Phi_{B,2}) + (S_{i,P} \cdot \Phi_{P,2}) \quad (2)$$

Equations 1 and 2 show the formulae for the pair of three component mixture designs, where S is the signal from a particular miRNA i and Φ is the fraction of total RNA for each tissue (liver = L , brain = B , and placenta = P) in mixtures 1 and 2. For example, using mixture proportions of 1:1:2 and 1:2:1 ($L:B:P$) provides corresponding Φ of 0.25, 0.25, 0.5 and 0.25, 0.5, 0.25, respectively. With this design, the maximum possible ratio ($S_{i,Mix1}/S_{i,Mix2}$) for any miRNA in the final mixture comparison corresponds to a 2-fold difference (i.e., log2 difference between Mix1 and

Mix2 of -1 or 1) which would be observed for brain-specific or placenta-specific miRNAs. For miRNAs that are not tissue-selective, some signals will be contributed from each component, resulting in ratios falling somewhere within that range. Estimating mixture signals from measured signals of unmixed tissues using in silico modeling with Eqs. 1 and 2 provides predicted values for comparison to observed results for Mix1 and Mix2.

Ratio estimates

The first two rounds of measurement (Rounds 1 and 2, not shown) were pilot studies used for tissue profiling alone, and did not include mixtures. A total of 7 sites participated in the three rounds (Rounds 3 to 5) that included the three pure RNA samples and the two mixtures of them. In each of these rounds, each site received three replicates for each of the 5 samples, with sample identities hidden. Participants profiled miRNA expression with the platforms used in their routine

workflow (one site used two different platforms). Labs using genome-scale platforms reported all detectable miRNAs. Labs using RT-PCR performed assays for a subset of miRNAs of interest to confirm that the mixtures could produce observed ratios similar to predicted values.

Log2 transformed ratio estimates for miRNAs were calculated for each round and compared across multiple participants. For analysis of genome-scale data, detectable miRNAs (counts ≥ 1 in any one sample) were normalized to the median total count among the samples and then log2 transformed. However, raw count tables, as well as datasets preprocessed with other strategies, could also be used as input. For RT-PCR data, the quantitation cycle (Cq) values were negatively transformed to provide comparable log2 transformed data. Predicted log2 ratios were calculated from the pair-wise differences of the modeled mixtures derived from Eqs. 1 and 2 using the linear transformed means for each pure tissue component, S_i . Observed log2 ratios were estimated from the pair-wise differences between means for each mixture, Mix1 and Mix2, described in Methods.

Visualizations and analyses

For the sites using genome-scale technologies, the log2 ratios for all detectable miRNA can be visualized using a Bland-Altman plot [15] to evaluate the ratio data throughout the dynamic range, and any miRNA that are highly enriched in one tissue relative to the other tissues should approach the benchmark values of the mixture designs.

In Fig. 3, the *predicted* ratios for all detected miRNA were calculated using Eqs. 1 and 2. The tissue-selective miRNA (those miRNA that are at least 10 times more prevalent in one tissue relative to the others) are derived from comparisons of the profiles of the three pure RNA samples included in the sample set, and are color-coded according to tissue type as in Fig. 1. Panels A to D represent multiple sites using different NGS platforms, with different sequencing depths. One site (panel A) was able to detect 1130 miRNA consistently across the 15 samples in the set, with 107 brain-selective and 105 placenta-selective miRNA with log2 ratios distinguishable from the “1-to-1” class, 59 miRNA with predicted log2 ratios of approximately zero (i.e., no difference between Mix1 and Mix2). The 1-to-1 class includes 23 liver-selective miRNA and 36 miRNA with approximately equal amounts of signal for brain and placenta. For much of the dynamic range the tissue-selective miRNA are predicted to approximate the designed-in log2 ratio limits of ± 1 . In comparison, another site (panel D) using a different NGS platform producing fewer reads and detected 291 miRNA in total. Of those, only 18 brain-selective, 9 placenta-selective, and 16 miRNA predicted to be 1-to-1 were identified. Panel E

shows the results from the site using a hybridization-based platform [16]. The large cluster of non-selective (NS) miRNA near the low end of the dynamic range is consistent with a background level of hybridization and this type of additive noise is known to contribute to ratio compression. One site (panel F, circles) used a multiplexed PCR platform targeting 32 different miRNA that were selected for their presence on common fixed content platforms [17]. Based on modeling of the data from the microarray study [13], two additional PCR sites were asked to measure a subset of miRNAs predicted to provide differences between mixtures: ~ 2 -fold up for miR-451a and miR-335; ~ 2 -fold down for miR-125b and miR-218; and no change for miR-375. One PCR site measured all five miRNAs in Round 3 (panel F, squares) and the other site measured two (panel F, triangles). Detection metrics are part of the summary table included in the dashboard view for each site and round (Additional file 1).

Figure 4 shows the experimentally *observed* ratios for miRNAs in Mix1 and Mix2 (see Fig. 1 for composition) and corresponds to the same labs displayed in Fig. 3, panels A to F. There is more dispersion in the observed log2 ratio data when compared to the predicted values, which also becomes more apparent at the lower end of the dynamic range. This is expected in part because the predicted log2 ratios are bounded by Eqs. 1 and 2 and use the averages of the three pure samples in both equations. For the subset miRNAs measured with PCR (Fig. 4f), the observed ratios confirm that the mixture design provides the predicted differences. Estimation of the useable region of the dynamic range based upon deviation from benchmark log2 ratios has been described for mRNA measurements using microarrays [9]. This metric relies on the subset of tissue-selective miRNAs to behave similarly to log2 ratio values derived directly from the mixture proportions. However, as shown in Fig. 3, measuring the pure tissue components provides predicted log2 ratio values for every detected miRNA, and these can be used for direct comparison to the corresponding observed log2 ratios. By assessing the deviation from predicted log2 ratios for all observed values, the entire measurement system can be evaluated using all miRNA regardless of their level of enrichment in any single tissue component. Figure 5 shows these differences for the same data as Figs. 3 and 4. As summary metrics for the overall measurement system, the median deviation value can be used as an indicator of bias and the inter-quartile range (IQR) can be used as an estimate of precision (solid and dashed horizontal lines, respectively). An IQR for each tissue-selective classification can also be determined (see Fig. 6).

It is clear that the majority of values falling outside the IQR occur at the lower end of the dynamic range. A




Fig. 3 Predicted distribution of log2 ratios. Panels A to F correspond to measurement processes A to F described in Results. For each datapoint in panels A to F, the difference between the predicted Mix1 and Mix2 log2 signals (log2 ratios) is plotted against their average for each detected miRNA. Signal values for each mixture are predicted using Eqs. 1 and 2. Filled circles correspond to predicted values for tissue-selective miRNA (those miRNA that are at least 10 times more prevalent in one pure total RNA tissue type relative to the other two) or miRNA that were approximately equal in relative abundance between placenta and brain (1-to-1): red = placenta-selective, blue = brain-selective, and yellow = 1-to-1 (liver-selective and placenta = brain). Open circles correspond to detectable, but non-selective miRNA. Red, yellow, and blue transparent bands indicate the 95% confidence interval for the loess (locally weighted smoothing) function (black lines) for the placenta, 1-to-1, and brain subsets, respectively. Panel F includes data from three different PCR labs: one site using multiplexed PCR (circles) and two sites using individual PCR assays (squares and triangles). Five miRNA of interest are highlighted: miR-451a (red), miR-335 (orange), miR-375 (yellow), miR-218 (green), miR-125b (blue). The total number of detectable miRNA and their tissue-selective classification are included in the summary table of the dashboard




Fig. 4 Observed distribution of log2 ratios. Panels A to F correspond to measurement processes A to F described in Results. For each datapoint in panels A to F, the difference between the Mix1 and Mix2 log2 signals (log2 ratios) is plotted against their average for each detected miRNA. Filled circles correspond to observed values for tissue-selective miRNA (those miRNA that are at least 10 times more prevalent in one pure total RNA tissue type relative to the other two) or miRNA that were approximately equal in relative abundance between placenta and brain (1-to-1): red = placenta-selective, blue = brain-selective, and yellow = 1-to-1 (liver-selective and placenta = brain). Open circles correspond to detectable, but non-selective miRNA. Red, yellow, and blue transparent bands indicate the 95% confidence interval for the loess (locally weighted smoothing) function (black lines) for the placenta, 1-to-1, and brain subsets, respectively. Panel F includes data from three different PCR labs: one site using multiplexed PCR (circles) and two sites using individual PCR assays (squares and triangles). Five miRNA of interest are highlighted: miR-451a (red), miR-335 (orange), miR-375 (yellow), miR-218 (green), miR-125b (blue)

lower limit for the useable range of the measurement system can be determined for a particular level of tolerance for deviation – for example, modeling how the distribution of deviation changes along the dynamic range and locating the lowest average log2 signal for which at

least 95% of the modeled distribution falls within one half fold-change (± 0.585 log2 difference). This lower limit and the maximum value demarcate the reliable region of the dynamic range in Fig. 5. A tolerance for deviation can also be used to define the upper limit




Fig. 5 Deviation from predicted ratios as a function of dynamic range. Panels A to F correspond to measurement processes A to F described in Results. Each datapoint in panels A to F represents the difference between the observed and predicted log₂ ratios plotted against the average observed and predicted log₂ signal for each detected miRNA. Open circles correspond to all detectable non-selective miRNA and yellow, blue, and red filled circles correspond to 1-to-1, brain-, and placenta-selective miRNA, respectively. The median and interquartile range (IQR) of the deviation from predicted for all detected miRNA are indicated by the solid and dashed horizontal lines, respectively. The lower limit of acceptable dispersion (determined by a user selectable deviation of ± 0.585 log₂, see Results) and the maximum detectable value are indicated by the margins of the darker grey areas, respectively. Margins were not assessed in Panel F. Panel F includes data from three different PCR labs: one site using multiplexed PCR (circles) and two sites using individual PCR assays (squares and triangles). Five miRNA of interest are highlighted: miR-451a (red), miR-335 (orange), miR-375 (yellow), miR-218 (green), miR-125b (blue). *Limits and range included in the summary table of the dashboard*

for technologies that may experience performance declines at higher signals, for example saturation in microarrays [9].

The tissue-selective subsets provide both true positive (brain and placenta) and true negative (1-to-1)

classifications useful for preparing receiver-operating characteristic (ROC) curves, and the area under the curve (AUC) can be used as a summary metric [7]. For each site, the tissue-selective miRNA are ranked by *P*-values using a paired t-test comparison of the log₂




Fig. 6 Bias and dispersion within tissue-selective classes. Panels A to E correspond to measurement processes A to E described in Results. The bias and dispersion for each tissue-selective class is shown in box (IQR) and whisker (1.5*IQR) format with outliers represented by black hash marks and median values indicated by black line (yellow = 1-to-1, blue = brain, red = placenta, and grey = none-selective (NS)). The median and interquartile range (IQR) of the deviation from predicted for all detected miRNA are indicated by the solid and dashed horizontal lines, respectively

signals for the three replicate Mix1 and Mix2 samples. Figure 7 shows the corresponding ROC curves for all detected tissue-selective data as well as the ROC curves derived from data within the reliable region of the dynamic range described in Fig. 5. Within a laboratory, both the AUC and the reliable range can be used to monitor alterations in performance introduced by changes in technology, reagents, or operator experience [7–9]. However, the AUC metric is limited by the availability of true positive and true negative differences identified by the pure sample profiles, and direct comparisons between different measurement systems may not be meaningful if there is a significant difference in the number of miRNA being assessed. Range limitations and AUC values per site and round are included in Table 1 and in the metrics tables of Additional file 1.

Proportion-based metrics

While ratio based metrics are useful for evaluating a site's ability to accurately detect differences between samples, evaluating the measurements for each individual mixture may provide additional information. A model can be fit based on Eqs. 1 and 2, and solved for the expected proportions of Φ (see above) given the set of signals, S_i . Genome-scale data can confidently estimate these proportions from the collected data for each pure component and mixture. Deviations from the designed proportions can be visualized using *target* plots (Fig. 8) [10]. The (x, y) coordinates for the center of each target correspond to the designed proportions and the (x, y) coordinates for the end of each line segment emanating from the center correspond to the estimated proportions of each pure tissue component in Mix1 and




Fig. 7 Discrimination accuracy. Panels A to E correspond to measurement processes A to E described in Results. Receiver-Operating Characteristic Curves (ROCplots), where true positives correspond to 10X placenta and 10X brain miRNA; and true negatives correspond to 1-to-1 components using either the entire detectable range (solid line) or limited to the reliable region (dashed line). Area under the curve (AUC) values are included in the summary table of the dashboard

Mix2, respectively. The lengths of these line segments provide an indication of potential bias in the measurement process. Part of this deviation is due to intrinsic differences in the miRNA content of each pure tissue, seen in the consistency of the direction of the yellow and red lines across labs. An mRNA fraction effect has been observed for transcriptomic measurements, and a means to assess this has been developed using RNA spike-in controls simulating poly-A mRNA [18]. The proportion estimates and bias indicators for each component are included in the metrics table of the dashboard. The sum of all lengths may provide a single useful indicator and is included in the dashboard summaries and in Tables 1, 2 and 3. The ellipses surrounding the line segment ends indicate the 95% confidence intervals for the estimated proportions of each component in Mix1 and Mix2 and are influenced by a

combination of both dispersion and detection within each tissue-selective class. Indications of poor precision are apparent in the measurement process shown in panel D in both Figs. 6 and 8.

Minimizing the experimental design

It should be noted that each round of the study included three replicates each of three pure total RNAs, and three replicates each of two mixtures for a total of 15 samples, and predicted values were derived from and compared with samples processed at the same time. Figures 2, 3, 4, 5, 6, 7 and 8 and the data in Table 1 correspond to these within round comparisons using three replicates. Modifying the experimental design to minimize the number of samples required may be accomplished in two ways.

First, pure total RNA, prepared as part of large enough batch to provide mixture samples that span several

Table 1 Summary metrics derived from complete reference sample sets: five samples, three replicates each, and three rounds

Measurement		Technology	Data Source			miRNA Detected			Log2 Signals			AUC ^c		Deviation			
Process			by Round	Non-Selective	TrueNeg 1-to-1 ^a	TruePos		Lower Limit ^b	Upper Limit	Range	All	Within Range	Log2 Ratio	Proportion Sum			
						Pure	Mixes								Reps	Brain	Placenta
A	NGS	3	3	3	928	56	103	104	5.8	20.0	14.3	0.959	0.996	-0.013	0.303	0.375	
		4	4	3	935	72	101	105	5.7	20.2	14.5	0.977	0.990	0.007	0.309	0.384	
		5	5	3	859	59	107	105	6.3	20.3	13.9	0.909	0.963	-0.053	0.373	0.355	
B	NGS	3	3	3	868	56	134	47	7.3	20.2	12.8	0.905	0.953	-0.085	0.387	0.508	
		4	4	3	721	38	102	58	5.7	19.0	13.2	0.922	0.951	-0.078	0.328	0.388	
		5	5	3	641	43	78	44	5.8	19.2	13.4	0.906	0.928	-0.052	0.322	0.389	
C	NGS	3	3	3	421	35	29	49	5.3	16.3	11.0	0.944	0.971	0.030	0.266	0.332	
		4	4	3	277	22	16	30	6.3	11.8	5.6	0.831	0.829	0.088	0.557	0.359	
		5	5	3	433	29	24	31	10.9	12.4	1.5	0.853	ND ^d	-0.104	0.875	0.480	
D	NGS	3	3	3	248	16	18	9	8.6	10.6	2.0	0.781	ND ^d	-0.124	0.627	0.803	
		4	4	3	290	13	13	2	6.6	10.6	4.0	0.956	ND ^d	-0.134	0.534	0.402	
E	Digital Hybridization	3	3	3	693	65	8	24	7.1	13.3	6.1	0.947	1.000	-0.075	0.392	0.460	
		4	4	3	633	17	8	23	5.6	14.4	8.8	0.985	0.997	-0.095	0.379	0.304	
		5	5	3	586	52	16	37	13.9	15.3	1.4	0.882	1.000	-0.238	0.599	0.473	

^aLiver-selective miRNA or miRNA with approximately equal signals in both brain and placenta
^bLower limits for NGS and digital hybridization were calculated with at 95% of values falling within ± 0.585 log2 difference from mean
^cROC curves were prepared with P-values using three replicates of Mix1 and Mix2
^dNot determined (ND) due to insufficient number of true negative or true positive values




Fig. 8 Deconvolved mixture proportions of tissue components in Mix1 and Mix2. Panels A to E correspond to measurement processes A to E described in Results. Concentric circles added to target values for emphasis. Line segments connect target values (central point of circles) to their corresponding estimates. Ellipses show the 95% confidence interval range of the mixture proportions for the three tissue components (yellow = liver, blue = brain, and red = placenta)

rounds may provide a sufficient baseline in the first round to allow for subsequent rounds of testing to be based on the paired mixtures alone, reducing the number of samples required for processing to six. To test this, we used the Round 3 pure tissue profiles as the baseline predicted values for comparison with the mixtures in the subsequent rounds. Metrics derived from this baseline approach are included in Table 2. Using predicted data derived from Round 3 pure samples alone neither obscures, nor distorts the differences among the measurement processes shown in Table 1. This indicates that using the paired mixtures alone, after establishing a baseline prediction, might be sufficient for monitoring processes over time. Intentional changes to a measurement process (e.g., reagent kits, instrumentation, or software) may require re-evaluation of the pure components. In this study, aliquots initially

prepared as part of one large set of samples prior to Round 3 were distributed to participants every six months for Rounds 4 and 5. Reference sample stability for longer periods has not been evaluated.

The second approach to reducing the number of samples would be running the sample set (brain, liver, placenta, Mix1, and Mix2) without replicates. To test this we limited the analysis to the first replicate of each dataset. Metrics derived from this approach are included in Table 3. In this case, the ROC curves derived from datasets without sample replication are based on ordered ratios instead of *P*-values [7]. In the absence of technical replication, the resulting AUCs are lower when all tissue-selective miRNA are evaluated, the lower limit of the useable range is higher, and the IQR is increased. Therefore a consistent approach, either with or without replication, should be used when tracking a

Table 2 Summary metrics derived from using pure samples from Round 3 for baseline predictions

Measurement		Technology	Data Source			miRNA Detected			Log2 Signals			AUC ^c		Deviation						
Process			by Round	Pure	Mixes	Reps	Non-Selective	TrueNeg	1-to-1 ^a	TruePos		Lower Limit ^b	Upper Limit	Range	All	Within Range	Log2 Ratio	Median	IQR	Proportion Sum
										Brain	Placenta									
A	NGS		3	3	3	3	928	56	103	104	5.8	20.0	14.3	0.959	0.996	-0.013	0.303			0.375
				4	3						5.4	20.2	14.8	0.966	0.988	-0.006	0.311			0.358
				5	3						6.3	20.0	13.8	0.899	0.938	-0.059	0.380			0.361
B	NGS		3	3	3	3	868	56	134	47	7.3	20.2	12.8	0.905	0.953	-0.085	0.387			0.508
				4	3						6.3	19.5	13.2	0.866	0.932	-0.092	0.399			0.448
				5	3						6.7	19.7	12.9	0.848	0.904	-0.435	0.397			0.565
C	NGS		3	3	3	3	421	35	29	49	5.3	16.3	11.0	0.944	0.971	0.030	0.266			0.332
				4	3						11.1	16.1	5.0	0.831	0.850	0.040	0.626			0.460
				5	3						15.7	15.7	0.0	0.848	ND ^d	-0.124	0.839			0.556
D	NGS		3	3	3	3	248	16	18	9	8.6	10.6	2.0	0.781	ND ^d	-0.124	0.627			0.803
				4	3						6.1	10.7	4.6	0.956	1.000	-0.178	0.539			0.645
E	Digital Hybridization		3	3	3	3	693	65	8	24	7.1	13.3	6.1	0.947	1.000	-0.075	0.392			0.460
				4	3						7.7	13.7	6.0	0.949	1.000	-0.260	0.495			0.532
				5	3						13.2	14.4	1.1	0.925	ND ^d	-0.257	0.680			0.579

^aLiver-selective miRNA or mRNA with approximately equal signals in both brain and placenta
^bLower limits for NGS and digital hybridization were calculated with at 95% of values falling within ± 0.585 log2 difference from mean
^cROC curves were prepared with P-values using three replicates of Mix1 and Mix2
^dNot determined (ND) due to insufficient number of true negative or true positive values

Table 3 Summary metrics derived from using one replicate of each sample per round

Measurement	Process	Technology	Data Source			miRNA Detected				Log ₂ Signals			AUC ^c		Deviation		
			by Round		Reps	Non-Selective	TrueNeg	TruePos		Lower Limit ^b	Upper Limit	Range	All	Within Range	Log ₂ Ratio		Proportion Sum
			Pure	Mixes				Brain	Placenta						Median	IQR	
A	NGS		3	3	1	671	43	93	89	7.1	20.0	12.9	0.856	1.000	0.094	0.386	0.394
			4	4	1	696	51	98	91	8.0	20.2	12.2	0.921	0.996	0.081	0.492	0.399
			5	5	1	692	36	96	95	9.5	20.2	10.8	0.793	0.971	-0.102	0.545	0.323
B	NGS		3	3	1	618	35	109	37	8.9	20.1	11.2	0.832	0.969	-0.055	0.405	0.559
			4	4	1	527	35	97	33	8.0	19.0	11.0	0.910	0.972	-0.106	0.384	0.417
			5	5	1	455	28	73	32	7.8	19.2	11.4	0.849	1.000	-0.031	0.354	0.456
C	NGS		3	3	1	326	11	26	39	6.6	16.3	9.7	0.905	0.983	0.030	0.323	0.348
			4	4	1	158	12	15	4	8.4	11.8	3.5	0.704	1.000	0.001	0.617	0.382
			5	5	1	247	13	18	15	12.0	12.5	0.5	0.795	ND ^d	-0.031	0.756	0.498
D	NGS		3	3	1	151	6	18	3	–	10.5	–	0.648	ND ^d	-0.235	0.969	0.644
			4	4	1	205	13	20	3	7.6	10.5	3.0	0.903	0.950	-0.126	0.569	0.471
E	Digital Hybridization		3	3	1	702	63	6	19	13.2	13.4	0.2	0.898	ND ^d	-0.077	0.661	0.635
			4	4	1	618	27	12	24	14.6	15.4	0.8	0.727	ND ^d	-0.340	0.670	0.376
			5	5	1	599	38	17	37	7.5	15.3	7.9	0.774	1.000	-0.165	0.749	0.511

^aLiver-selective miRNA or miRNA with approximately equal signals in both brain and placenta

^bLower limits for NGS and digital hybridization were calculated with at 95% of values falling within ± 0.585 log₂ difference from mean

^cROC curves were prepared using ordered log₂ ratios and a single replicate

^dNot determined (ND) due to insufficient number of true negative or true positive values

measurement process over time. It should also be noted that, in the absence of replication, a measurement failure for any one of the five samples in the set would render some of the metrics indeterminable.

Discussion

The total RNA reference sample set described here provides process controls for genome-scale measurements of miRNA that are reasonable biological mimics and provide a sufficient number of miRNAs to span the dynamic range of a measurement system. Evaluation of the deviations in ratios designed into the sample set provides a quantitative assessment of the reliable region of the measurement system. These sample sets, with or without replication and with or without baseline, can be run in parallel with or in between biomarker profiling experiments at some frequency to provide ongoing measurement assurance of the complete measurement process. An observation of poor results with the process controls (lower AUC, decreased reliable range, etc.) may indicate that profiling experiment results from a proximal time-frame may also have issues. However, achieving an acceptable result with the process controls only indicates that a *measurement process* is working well, but does not confirm experimental observations on the samples under study.

This study was designed to evaluate the reference samples and develop associated metrics, and is not intended as a platform comparison. The results presented are from those sites that accepted samples for the rounds that included mixtures and subsequently provided data for analysis. The platforms are intentionally obscured in the main text because platform performance is confounded with site performance in this study. Less than optimal performance at a particular site due to other factors (operator experience, etc.) may give the impression of poor platform performance. Measurement processes A and B are the only processes performed by two different sites using the same platform. Measurement processes C and D were performed at a single site using two different platforms (both different from the platform used in A and B). Measurement processes E and F are unique sites and platforms. Additional details for each measurement process, including platform information, are available in Additional file 2 as outlines of the protocols in place at the labs. These protocols are not intended as recommendations or guidelines. This study demonstrates the utility of these mixture samples and associated metrics to evaluate technical performance of any genome-scale measurement process, the methods and protocols are incidental to the study presented here.

The current dataset collection provides a range of performance and demonstrates that the samples, the

visualizations presented in Figs. 2, 3, 4, 5, 6, 7 and 8, and the summary metrics shown in Table 1 can be used to discern differences in performance. Systematic application of the samples, metrics, and methods described here can enable evaluation and optimization of both laboratory and measurement platform performance. Evaluating the relationship between protocols used at different sites and observed performance may also be useful to identify key parameters for optimization.

To promote periodic self-assessment of genome-scale measurement system performance, a web-based version of the analysis pipeline has been implemented as part of the EDRN Informatics Center [<https://edrn.nci.nih.gov/microna>]. Dashboard views of the results can also be generated online (see Additional file 3 for instructions). Visitors to the site may view descriptions of available reference samples or download a protocol on how to prepare them in their own laboratory [14] (a brief description is available in Methods). Visitors may also view or download publicly available datasets and results. Current participants can add to their datasets and compare the new results to prior datasets to assess individual site performance over time. For new sites interested in assessing their genome-scale profiling workflows, information about registration and availability of EDRN prepared reference sample sets is provided at the EDRN website.

Conclusions

Metrics and visualizations derived from mixture samples are well suited for assessing performance of genome-scale measurement systems used to identify differentially regulated miRNAs. They are made from biological materials similar to those studied by biomarker profiling laboratories and provide a sufficient number of differentially expressed miRNAs with predictable ratios to serve as benchmarks. Implementing these metrics and visualizations as part of an online resource offers laboratories the opportunity to evaluate and optimize their discovery process.

Methods

Mixture design

Human Brain Reference RNA (Cat. No. AM6050), Human Liver Total RNA (Cat. No. AM7960), and Human Placenta Total RNA (Cat. No. AM7950) was obtained from Ambion (Thermo Fisher Scientific). Manufacturer's stock solutions of 1 µg/µl were verified on a Qubit (Thermo Fisher Scientific). If necessary, stock solutions of pure tissue components (same lot numbers) were combined to provide a sufficient volume of identical material prior to distribution. Prior to mixing, an adequate portion of stock solutions are set aside for pure tissue aliquots. The remaining liver, brain, and placenta stocks were then mixed by volume using the proportions

of 1:1:2 and 1:2:1 for Mix1 and Mix2, respectively. These five samples (three neat tissues and two mixtures) were then divided into aliquots. Three replicates of each sample were distributed to participants as a numbered blinded set of 15 tubes. A general method for the preparation of two mixtures of total RNA (Mix1 and Mix2) derived from three different pure total RNA sources (RNA1, RNA2, and RNA3) from either commercially available or laboratory prepared total RNA is also available [14]. This protocol allows labs to recreate previously measured sample designs for comparison or to generate new sample designs with different components and/or mixture formulations.

Sample handling and analysis

Each laboratory used its routine protocol for miRNA biomarker detection and evaluations. Individual protocols are available online as part of the data repository, and included in Additional file 2.

Additional files

Additional file 1: Dashboard views of measurement processes A – E from Rounds 3–5, using three replicates. (PDF 1960 kb)

Additional file 2: Protocols for measurement processes A – F. (PDF 395 kb)

Additional file 3: Instructions for using measurement assurance pipeline online. (PDF 223 kb)

Abbreviations

Caltech: California Institute of Technology; EDRN: Early Detection Research Network; HYB: Hybridization; JPL: Jet Propulsion Laboratory; NASA: National Aeronautics and Space Administration; NCI: National Cancer Institute; NGS: Next-generation sequencing; NIST: National Institute of Standards and Technology; RT-PCR: Reverse transcription polymerase chain reaction

Acknowledgements

Not applicable

Funding

The work presented in this manuscript is jointly designed, executed and written under the auspices of an Interagency Agency Agreement between the National Cancer Institute and the National Institute of Standards and Technology, both of which are Federal Agencies supported by the funds from US Government. Additional funding comes from NCI-EDRN Grant numbers: U01CA214182, U01CA214195, U24CA115091. Part of the work was performed at JPL/Caltech under the contract to NASA, and at the Center for Data-Driven Discovery, Caltech.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article, its Additional files, and online at [https://edrn.nci.nih.gov/microrna].

Disclaimer

Certain commercial entities, equipment or materials may be identified in this document in order to describe an experimental procedure or concept adequately. Such identification is not intended to imply recommendation or endorsement by the National Institute of Standards and Technology, nor is it intended to imply that the entities, materials or equipment are necessarily the best available for the purpose.

Authors' contributions

PSP, LS, SS, and MLS designed the study. PSP, LKV, and MLS developed the reference samples. LKV, AS, GL, ACG, HIP, CG, SMD, KK, SAS, DK, KVJ, ACL, KLT, and BAR acquired and processed the data. PSP, SPL, and JRP developed

metrics and visualizations. PSP, AAM, LC, SCK, HK, and DJC developed the website. PSP drafted the manuscript. SPL, JRP, AAM, and LC contributed manuscript sections. All authors participated in the revision process and provided final approval.

Ethics approval and consent to participate

Not applicable. Human Brain Reference RNA (Cat. No. AM6050), Human Liver Total RNA (Cat. No. AM7960), and Human Placenta Total RNA (Cat. No. AM7950) was obtained from Ambion (Thermo Fisher Scientific).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Author details

¹Joint Initiative for Metrology in Biology, National Institute of Standards and Technology, 443 Via Ortega, Stanford, CA 94305, USA. ²Statistical Engineering Division, National Institute of Standards and Technology, Gaithersburg, MD, USA. ³Center for Data Driven Discovery, California Institute of Technology, Pasadena, CA, USA. ⁴Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA. ⁵Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. ⁶Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, USA. ⁷Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ⁸Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. ⁹Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. ¹⁰Translational Genomics Research Institute, Phoenix, AZ, USA. ¹¹Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. ¹²Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.

Received: 29 September 2017 Accepted: 25 January 2018

Published online: 06 March 2018

References

1. Srivastava S, Kramer BS. Early detection cancer research network. *Lab Invest.* 2000;80(8):1147–8.
2. Tan PK, et al. Evaluation of gene expression measurements from commercial microarray platforms. *Nucleic Acids Res.* 2003;31(19):5676–84.
3. MAQC Consortium. The MicroArray quality control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. *Nat Biotechnol.* 2006;24(9):1151–61.
4. SEQC/MAQC-III Consortium. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the sequencing quality control consortium. *Nat Biotechnol.* 2014;32(9):903–14.
5. Shippy R, et al. Using RNA sample titrations to assess microarray platform performance and normalization techniques. *Nat Biotechnol.* 2006;24(9):1123–31.
6. Thompson KL, et al. Use of a mixed tissue RNA design for performance assessments on multiple microarray formats. *Nucleic Acids Res.* 2005;33(22):e187.
7. Pine PS, et al. Use of diagnostic accuracy as a metric for evaluating laboratory proficiency with microarray assays using mixed-tissue RNA reference samples. *Pharmacogenomics.* 2008;9(11):1753–63.
8. Thompson KL, Pine PS. Comparison of the diagnostic performance of human whole genome microarrays using mixed-tissue RNA reference samples. *Toxicol Lett.* 2009;186(1):58–61.
9. Pine PS, Rosenzweig BA, Thompson KL. An adaptable method using human mixed tissue ratiometric controls for benchmarking performance on gene expression microarrays in clinical laboratories. *BMC Biotechnol.* 2011;11:38.
10. Parsons J, et al. Using mixtures of biological samples as process controls for RNA-sequencing experiments. *BMC Genomics.* 2015;16:708.
11. Git A, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA.* 2010;16(5):991–1006.
12. Mestdagh P, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. *Nat Methods.* 2014;11(8):809–15.
13. Ach RA, Wang H, Curry B. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. *BMC Biotechnol.* 2008;8:69.

14. Vang LK, Pine PS, Munro SA, Salit ML. Preparation of a set of Total RNA benchmarking samples for performance assessment of genome-scale differential gene expression, NIST technical series number: NIST SP 1200–23; 2017. <https://doi.org/10.6028/nist.sp.1200-23>.
15. Bland JM, Altman DG. Measuring agreement in method comparison studies. *Stat Methods Med Res.* 1999;8(2):135–60.
16. Fortina P, Surrey S. Digital mRNA profiling. *Nat Biotechnol.* 2008;26:293–4.
17. Thompson K, Rosenzweig B, Pine PS. Tools for microRNA discovery: design and testing of controls for profiling platforms. *Toxicol Sci.* 2015;144(Suppl.1):2033A.
18. Munro SA, et al. Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures. *Nat Commun.* 2014;5:5125.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

